Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ligand Pharmaceuticals, Inc.

http://www.ligand.com

Latest From Ligand Pharmaceuticals, Inc.

News We're Watching: GE, Biofourmis Partnership, Tricuspid Procedure Boom, Boston Scientific Borrows $2Bn, And More

Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, GE Healthcare and Biofourmis announced a deal to collaborate on virtual care; Cleerly touts a new CPT code for its Ischemia cardiac diagnostic software; Boston Scientific announced how it plans to pay for Axonics; a Wells Fargo survey suggests the market for transcatheter tricuspid valve repair and replacement will grow faster than previously imagined; Virtual Incision earns FDA de novo authorization for its MIRA miniaturized surgical system for colectomy procedures; and MMI and Fabric announce major financing rounds.

News We're Watching Approvals

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.

Scrip Asks Clinical Trials

FDA’s Dry January: Little Novel Application Activity, But That Doesn’t Mean No Fun

US FDA’s drugs center posted one of its lowest monthly approval counts of original applications in January, but new indications filled the gap, including new claims for Merck’s Keytruda, Takeda immunoglobulins, and Sanofi/Regeneron’s Dupixent.

US FDA Performance Tracker Approvals

As 2024 Begins, US FDA’s Novel Agent Prospects Look A Lot Like 2023

Immuno-oncology will remain a major force at both FDA’s drugs and biologics centers, but watch for psychiatry and antibiotics to make some noise; rare pediatric diseases will remain prominent as the priority review voucher program heads into the sunset.

US FDA Performance Tracker Drug Review
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Biotechnology
    • Drug Discovery Tools
    • Transgenics
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Ab Initio Biotherapeutics
    • Crystal Bioscience, Inc.
    • CyDex Pharmaceuticals, Inc.
    • Icagen Pharmaceuticals, Inc.
    • Metabasis Therapeutics, Inc.
    • Neurogen Corporation
    • Pharmacopeia, Inc.
    • Pfenex Inc.
    • Verrow Pharmaceuticals, Inc.
    • Vernalis Group plc
    • Cita NeuroPharmaceuticals
    • Taurus Biosciences LLC
    • xCella Biosciences, Inc.
UsernamePublicRestriction

Register